Physician profile
Anjali Kapur
NPI 1083118202
$3,027.40
in general payments reported to CMS, 2019-2025
9 companies · $2,002 in 2025
The $2,002 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Urology) provider received nationally (typical 2025 total: $782).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,026 · 2025: $2,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357 · Travel and Lodging: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,356.92 |
| Travel and Lodging | $670.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,552.13 | 2024-2025 | Solyx Sis System, Lynx System, Bulkamid |
| Medtronic, INC. | $902.59 | 2024-2025 | Interstim, Altaviva |
| Ferring Pharmaceuticals INC. | $154.50 | 2025 | Adstiladrin |
| Abbvie INC. | $136.64 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $124.38 | 2025 | Bard Urinary Drainage Bag |
| Davol INC. | $71.15 | 2025 | Arista |
| Teleflex LLC | $38.79 | 2024 | Solesta |
| Valencia Technologies Corporation | $27.12 | 2025 | Ecoin Device Kit |
| Millicent US INC | $20.10 | 2025 | Intrarosa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjali Kapur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.